Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
Axonics Names Michael H. Carrel as Chairman of its Board of Directors
10:00am, Wednesday, 29'th Apr 2020
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment
AtriCure reports Q1 EPS (42c), consensus (41c) ATRC
09:02am, Wednesday, 29'th Apr 2020
AtriCure reports Q1 EPS (42c), consensus (41c) ATRC
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
12:00am, Wednesday, 29'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs April 28.)
AstraZeneca plc (NYSE:...
Untreated heart attacks negative for Abiomed, says Piper Sandler ABMD;BSX;MDT;ATRC
10:10am, Tuesday, 28'th Apr 2020
Untreated heart attacks negative for Abiomed, says Piper Sandler Piper Sandler ABMD BSX MDT ATRC
JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $39
12:00am, Tuesday, 28'th Apr 2020AtriCure to Participate at Upcoming Investor Conferences
08:02pm, Monday, 27'th Apr 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat
AtriCure (NASDAQ:ATRC) Rating Lowered to Hold at BidaskClub
05:12am, Monday, 27'th Apr 2020
AtriCure (NASDAQ:ATRC) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Saturday, BidAskClub reports. Several other analysts also recentl
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
08:37pm, Sunday, 26'th Apr 2020
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week,...
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
04:31pm, Wednesday, 22'nd Apr 2020
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
04:31pm, Wednesday, 22'nd Apr 2020
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure (ATRC) to Release Quarterly Earnings on Wednesday
06:56am, Wednesday, 22'nd Apr 2020
AtriCure (NASDAQ:ATRC) is scheduled to announce its earnings results after the market closes on Wednesday, April 29th. Analysts expect the company to announce earnings of ($0.37) per share for the qua
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
12:00am, Wednesday, 22'nd Apr 2020AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky Sells 10,000 Shares of Stock
08:44am, Tuesday, 21'st Apr 2020
AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 10,000 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $40.00, for a total value
AtriCure (NASDAQ:ATRC) Coverage Initiated by Analysts at Oppenheimer
05:22am, Tuesday, 21'st Apr 2020
Research analysts at Oppenheimer initiated coverage on shares of AtriCure (NASDAQ:ATRC) in a research report issued to clients and investors on Sunday, Benzinga reports. The firm set an “outperform�
AtriCure Inc. (NASDAQ:ATRC) Shares Purchased by Ladenburg Thalmann Financial Services Inc.
10:58am, Sunday, 19'th Apr 2020
Ladenburg Thalmann Financial Services Inc. boosted its position in AtriCure Inc. (NASDAQ:ATRC) by 770.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange
